Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb gets FDA approval for Orencia

Bristol-Myers Squibb gets FDA approval for Orencia

5th August 2011

Bristol-Myers Squibb has announced that the Food and Drug Administration (FDA) in the US has approved its subcutaneous formulation of Orencia.

The non-anti-TNF biologic for adults with rheumatoid arthritis is already available in Europe and is used to reduce signs and symptoms of the disorder.

Mark Genovese, professor of medicine and co-chief of Stanford University Medical Center's division of immunology and rheumatology, commented that the Orencia self-injectable (SC) treatment showed similar efficacy and safety compared with Orencia IV.

"Physicians now have a new option of a non anti-TNF, with a different mechanism of action, when administering a biologic in a subcutaneous formulation," he added.

Professor Genovese pointed out that having an increased range of options is very important to both patients and healthcare professionals dealing with the illness.

This news came just after Bristol-Myers Squibb unveiled its financial results for the second quarter of 2011, during which the company saw its sales rise 14 percent.ADNFCR-8000103-ID-800690890-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.